APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Summary

Background Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. Methods and findings We report here a novel update (2012–2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers—total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42—in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. Conclusions Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.

Related articles

• Dosage Calculations in Nursing

  This document provides a comprehensive overview of dosage calculations in nursing, emphasizing the importance of precision in medication administration using various measurement systems, and highlighting common errors and guidelines for safe practice.

• The Dynamic Nurse-Patient Relationship, Function, Process and Principles

  This document discusses Ida Jean Pelletier's Deliberative Nursing Process Theory, emphasizing the interactive nature of nursing and the essential components involved in nurse-patient interactions. It outlines how critical thinking and reflective practice enhance patient care.

• The Dynamic Nurse-Patient Relationship: Function, Process and Principles

  This document discusses the Deliberative Nursing Process Theory conceptualized by Ida Jean Pelletier, highlighting its core principles and applications in nursing care. It emphasizes the dynamic interaction between nurses and patients and the importance of critical thinking in addressing patient needs.

• The Roy Adaptation Model: A Comprehensive Nursing Framework

  The Roy Adaptation Model is a nursing framework developed by Sister Callista Roy that emphasizes the person as a holistic adaptive system interacting with a changing environment, focusing on promoting adaptation to enhance health and quality of life.

• The Life of Martha Rogers

  Martha Rogers' Theory of Unitary Human Beings provides a revolutionary framework for nursing that emphasizes understanding humans as irreducible energy fields rather than merely treating symptoms. This theory integrates concepts from quantum physics and general system theory.